Conference Correspondent

Conference Correspondent

News, views, and coverage of important topics and discussions from oncology conferences and events.

Conference Correspondent | December 16, 2021
Nivolumab plus ipilimumab demonstrates deep and sustained confirmed responses for patients with metastatic uveal melanoma.
Conference Correspondent | December 16, 2021
Nivolumab plus ipilimumab demonstrated improvement in overall survival for patients with metastatic uveal melanoma.
Conference Correspondent | December 15, 2021
The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma.
Conference Correspondent | December 15, 2021
First-line treatment with relatlimab plus nivolumab demonstrated a statistically significant progression-free survival benefit compared with nivolumab monotherapy in patients with advanced melanoma.
Conference Correspondent | December 15, 2021
Neoadjuvant and adjuvant treatment with nivolumab plus relatlimab for resectable stage III melanoma achieved high pathologic complete response and major pathologic response rates.
Conference Correspondent | December 15, 2021
In a 6.5-year update of CheckMate-067, durable improvements in overall survival, progression-free survival, and objective response rate were observed with nivolumab plus ipilimumab over nivolumab alone as first-line therapy in patients with advanced melanoma, with no new safety signals.
Conference Correspondent | December 15, 2021
Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma.
Conference Correspondent | December 14, 2021
Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib.
Conference Correspondent | December 14, 2021
TGFβ is a cytokine that enhances myelofibrosis disease progression. AVID200, a TGFβ1/3 inhibitor, may provide clinical benefit manifesting as improved platelet counts in patients with myelofibrosis who have thrombocytopenia.
Conference Correspondent | December 14, 2021
JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data.
Page 1 of 15
Results 1 - 10 of 143

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code